TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06475417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab combined with DOS
Description: After signing the informed consent, they are screened to meet the inclusion criteria. After receiving the standard dose of adebrelimab combined with DOS regimen for 3 courses of treatment before surgery, and within 3-6 weeks after the completion of the third administration, preoperative imaging examination is used to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, The patient underwent radical surgical treatment for gastric cancer and observed pCR
Study: NCT06210074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daye Diagnostic Tampon
Description: The DAYE Diagnostic Tampon is a class A in vitro diagnostic device. It has CE certification (self-certified via a declaration of conformity, following the IVDR (EU) 2017/746).~The DDT is constructed entirely from woven cotton and consists of an absorbent core wrapped in a protective sleeve. The DDT is loaded in an applicator to aid with insertion. The DDT needs to be worn for 20 minutes then when removed should be placed immediately in the sterile container.
Study: NCT05376813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-Scan and MRI
Description: CT-Scan and MRI examination for shoulder will be performed on healthy volunteers.
Study: NCT04071821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetirizine HCl Gummy
Description: cetirizine HCl 10mg in a gummy formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetirizine HCl Gummy
Description: cetirizine HCl 10mg in a gummy formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetirizine HCl Gummy
Description: cetirizine HCl 10mg in a gummy formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetirizine HCl Gummy
Description: cetirizine HCl 10mg in a gummy formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec tablet 10mg
Description: cetirizine HCl 10mg tablet
Study: NCT06113900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab orally once daily
Description: Sodium glucose co-transporter 2 inhibitors
Study: NCT06143332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Aerobic exercise training on a cycle ergometer
Study: NCT05592106

Intervention type: DIAGNOSTIC_TEST
Intervention: T1 mapping on gadoxetic acid-enhanced MRI
Description: All subjects underwent 1.5T Gd-EOB-DTPA-enhanced MRI including pre-contrast and hepatobiliary-phase T1 mapping.
Study: NCT04468542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)
Description: 2-cc injection (mixture consisting of 1-cc of 0.5% Bupivacaine injection and 1cc of 40mg/cc triamcinolone acetonide suspension injection) will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Superior laryngeal nerve block - Placebo (saline)
Description: 2-cc injection of saline will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
Study: NCT05279144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventroguleal
Description: Vastus Lateralis
Study: NCT04049591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Higher Dose UFH
Description: Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lower Dose UFH
Description: Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
Study: NCT05203497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECT
Description: One single injection of 99mTc-ZHER2:41071, followed by gamma camera imaging after 2, 4, 6 and 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECT
Description: One single injection of 99mTc-ZHER2:41071, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
Study: NCT05564143

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided gastroenterostomy (EUS-GE)
Description: Treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic gastroenterostomy (LGE)
Description: Treatment
Study: NCT05969652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy slow resistance training
Description: Patients will perform the exercises in the concentric and eccentric phases with the maximum amount of weight tolerated at a rate of 3 seconds/repetition. The number of sets\*repetitions is given below. 2-3 minutes rest between sets will be given.~1st week 3\*15 2-3.week 3\*12 4th-5th week 3\*10 6th week 3\*8

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercise training
Description: Among the patients in the eccentric exercise group, only the eccentric phase of the exercises in the HSR group, will be asked to actively engage with the affected party. The eccentric contraction rate will be set to 6 seconds. Each exercise will be done 3 sets of 15 repetitions. In the next week, progress will be made in exercise intensity according to tolerance and 500 g will be added to the previous weight.~will be continued. If patients cannot tolerate the new weight or there is an increase in pain, the same weight will be continued for another week.
Study: NCT06242652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 608 Dose A
Description: 608 subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 608 Dose B
Description: 608 subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 608 Dose C
Description: 608 subcutaneous (SC) injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous (SC) injection.
Study: NCT06238258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPECTROM Training
Description: Training regarding treatment of behavioral challenges in adults with intellectual disability
Study: NCT06306716

Intervention type: DEVICE
Intervention: RENASYS Film with AIRLOCK Technology
Description: RENASYS Film with AIRLOCK Technology intended for use with Smith+Nephew RENASYS NPWT Systems
Study: NCT06221306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implant: NDI
Description: Placement of narrow diameter implants (NDI) (3.3) in the dentoalveolar ridge

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant: SDI
Description: Placement of standard diameter implants (SDI) (4.1) in the dentoalveolar ridge with simaltenous bone augmentation
Study: NCT06096402

Intervention type: PROCEDURE
Intervention: no intervention, but surgical practice as usual is continued. Its a pragmatic study
Description: no intervention

Intervention type: PROCEDURE
Intervention: no intervention, but surgical practice as usual is continued. Its a pragmatic study
Description: no intervention
Study: NCT04983407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: batiraxcept
Description: Batiraxcept is experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: batiraxcept
Description: Batiraxcept is experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel is active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel is active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Nab paclitaxel is active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine is active comparator
Study: NCT05710471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: Intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal injection
Study: NCT05959395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VectRx Thermal Therapy
Description: Subjects will receive VectRx thermal treatment added to 2 cycles of chemotherapy regimen. The VectRx device will be used under continuous investigator monitoring of internal tissue temperatures via real-time temperature probe data, as well as clinical signs and symptoms reflecting the objectives described above. Up to 5 study subjects will be treated. They will complete VectRx treatment during day 1 prior to 5-FU based (e.g., mFOLFIRINOX) or Gemcitabine based (e.g., Gemcitabine/Nab Paclitaxel) chemotherapy infusion. Thermal treatment will be carefully ramped-up to achieve staged goals of average tumor temperatures between 38°C and 43°C for total treatment times up to 30-70 minutes. The target temperature will be 41.5°C.
Study: NCT05739565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acti-Pair program
Description: Motivational support by the peer (a patient with the same pathology who meets the WHO recommendations for physical activity), who will provide motivational follow-up~* The implementation of a personalized and realistic physical activity project for the patient via the physical activity support systems (sport health centers)~* Support from health professionals (GP) via the prescription of physical activity and from adapted physical activity (APA) professionals
Study: NCT04702776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%
Description: Application of one drop of Humylub Ofteno® PF (Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) QID in both eyes (OU) during 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hyaluronate 0.15%
Description: Application of one drop of Hyabak® PF (Sodium hyaluronate 0.15%) QID in OU during 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hyaluronate 0.4%
Description: Application of one drop of Lagricel Ofteno® PF (Sodium Hyaluronate 0.4%) QID in OU during 30 days.
Study: NCT05179447

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy
Description: Internal radiation of the vaginal vault using a vaginal cylinder. For brachytherapy administered alone it is recommended: suggested dose is either 3 fractions of 7 Gy or 5 fractions of 6 Gy.~For brachytherapy administered after completion of External beam radiotherapy (EBRT):~Total dose should aim to be 65 Gy, and suggested dose is 2-3 fractions of 5-6 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal brachytherapy
Description: Internal radiation of the vaginal vault using a vaginal cylinder. For brachytherapy administered alone it is recommended: suggested dose is either 3 fractions of 7 Gy or 5 fractions of 6 Gy.~For brachytherapy administered after completion of External beam radiotherapy (EBRT):~Total dose should aim to be 65 Gy, and suggested dose is 2-3 fractions of 5-6 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiotherapy
Description: External beam pelvic radiotherapy on a linear accelerator, 45-50 Gy in 25-28 out-patients sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: No adjuvant therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemoradiation therapy
Description: 4 adjuvant cycles carboplatin and paclitaxel followed by External beam pelvic radiotherapy (45-50 Gy )
Study: NCT05141370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cataract surgery with CATSYS
Description: patient diagnosed with cataract requiring surgery will have an anterior capsulorhexis with CATSYS
Study: NCT05988775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leg training
Description: Participants sat on a chair with their left heel resting on the table with the push button switches. participants performed 10 blocks of the aforementioned sequence with their leg, with a 30s break between each block.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sequence observation
Description: Participants observed 10 blocks of the sequence with the lights alternating automatically, with a 30s break between each block.

Intervention type: OTHER
Group type: OTHER
Intervention: Nature movie watching
Description: Participants observed 10 blocks of the sequence with the lights alternating automatically, with a 30s break between each block.
Study: NCT05790382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM-101
Description: In Part 1, each cohort will receive a single dose at one of three dose levels (3 cohorts).~In Part 2, each cohort will receive multiple doses at one of four dose levels (4 cohorts).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for infusion
Study: NCT06132386

Intervention type: OTHER
Intervention: biopsy
Description: colorectal biopsy for tissue acquisition

Intervention type: OTHER
Intervention: biopsy
Description: colorectal biopsy for tissue acquisition

Intervention type: OTHER
Intervention: biopsy
Description: colorectal biopsy for tissue acquisition
Study: NCT04878003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administration by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895, administration by mouth
Study: NCT05397626

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart Rhythm Biofeedback
Description: Heart rhythm biofeedback is a non-invasive intervention intended to improve heart rate variability and physical resilience that is often limited in chronic fatigue syndrome

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart Rhythm Biofeedback
Description: Heart rhythm biofeedback is a non-invasive intervention intended to improve heart rate variability and physical resilience that is often limited in chronic fatigue syndrome

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen Water
Description: Hydrogen water, if ingested daily over several weeks, may have antioxidant and anti-inflammatory effects in chronic fatigue syndrome

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen Water
Description: Hydrogen water, if ingested daily over several weeks, may have antioxidant and anti-inflammatory effects in chronic fatigue syndrome

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combined treatment: Heart rhythm biofeedback plus hydrogen water
Description: This treatment is intended to explore the possible additive or synergistic effects of combining heart rhythm biofeedback and hydrogen water.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combined treatment: Heart rhythm biofeedback plus hydrogen water
Description: This treatment is intended to explore the possible additive or synergistic effects of combining heart rhythm biofeedback and hydrogen water.
Study: NCT03962374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frova
Description: Frova will be used to facilitate the endotracheal intubation. The success rate of first attempt of intubation will be assessed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stylet
Description: Stylet will be used to facilitate the endotracheal intubation. The success rate of first attempt of intubation will be assessed.
Study: NCT05896085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REThink game
Description: The Rethink therapeutic game is an online game developed based on Rational-Emotive Behavioral Therapy and has two versions: for children and adolescents and for adults. The Rethink therapeutic game for adults is available in 3D and VR version and consists of four levels, each of them training a specific emotion regulation ability such as: emotional awareness, mindfulness, cognitive change
Study: NCT04998435

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plain Block
Description: Using aseptic technique, ultrasound-guided ESPB will be performed with the patient in sitting position. The spinous process of the vertebra and a point 3 cm lateral to it will be marked before performing the block. The needle will be inserted and advanced under sono-visualization to contact the transverse process of the vertebra. After negative aspiration, LA will be deposited into the fascial plane deep to erector spinae muscle.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: Using sterile technique, ultrasound scanning of thoracic paravertebral space will be done in sitting position. The transverse process will be identified as hyperechoic structure while pleura will be identified as a mobile hypoechoic structure. The needle will be inserted cranio-caudal and advanced under sono-visualization to the identified thoracic paravertebral space. After negative aspiration, LA will be deposited displacing the pleura.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4.
Study: NCT05559489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Solution
Description: Effectiveness- implementation study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer
Description: Standard-of-care Intravenous Fluid resuscitation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer
Description: Standard-of-care Intravenous Fluid resuscitation
Study: NCT05744765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercises
Description: After the initial 5 minutes of relaxed breathing, the participants will perform diaphragmatic and costal breathing for 10 minutes. .5 diaphragmatic breathing will be done in 1 minute.
Study: NCT04452981

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VeNS
Description: The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VeNS
Description: The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
Study: NCT05768945

Intervention type: DRUG
Intervention: Semaglutide
Description: Semaglutide claim is used as the exposure group.

Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) claim is used as the reference group.
Study: NCT03788720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture of the ovarian cortex
Description: Suture of the ovarian cortex after laparoscopic enucleation of endometriomas, using one single monofilament suture material, continuous suture technique with maximum 5 transfixion of the ovarian cortex and intracorporeal knots only (no extracorporeal knots).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No suture of the ovarian cortex
Description: Laparoscopic enucleation of endometriomas without suture of the ovarian cortex
Study: NCT06443866

Intervention type: DIAGNOSTIC_TEST
Intervention: Disease status detection
Description: RAI dose determination

Intervention type: DIAGNOSTIC_TEST
Intervention: Theranostic dosimetry
Description: Theranostic dosimetric evaluation for optimization of RAI therapy of thyroid cancer

Intervention type: DRUG
Intervention: I-124 PET/CT imaging
Description: Theranostic dosimetry for optimization of RAI therapy for Thyroid Cancer
Study: NCT06438484

Intervention type: BEHAVIORAL
Intervention: multimodal prehabilitation program
Description: Patients performed physical exercise training and/or received dietary counseling for five weeks, provided by a trained physiotherapist and dietitian (both \>15 years experience). The physical exercise training consisted of high-intensity interval training (HIIT) three times a week and functional strengthening exercises. Patients visited the hospital two times a week and performed home exercise training five times a week on a stationary cycle ergometer (Corival Home+, Lode BV, Groningen, The Netherlands).~The dietary intervention consisted of optimization of energy and protein intake, optimization of timing of eating protein-rich products, and if necessary additional protein and vitamin supplements. Individual protein requirements were set at 1.5-1.9 g/kg fat free mass. Patients used the eiFIT-application or a food diary to track their protein intake.